MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
News & Events
September 22, 2016
MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day
August 10, 2016
MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
July 11, 2016
MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
June 1, 2016
Study of SHaRe Data Published in PNAS Demonstrates the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into HCM